AOD-9604 Weight Loss: Human Trial Results and Safety Evidence

AOD-9604 is a modified growth-hormone fragment investigated for weight loss. The human evidence reviewed here does not establish a convincing weight-loss benefit. Its larger oral obesity trial did not show a significant advantage over placebo at the main weight-loss endpoint. A later publication summarized safety from the same development program; it was not a new trial showing that AOD-9604 works. Understanding that trail is more useful than treating every paper, abstract or trial mention as another successful study. FDA evidence review, pages 20–23; 2013 safety publication.

Why is AOD-9604 discussed for fat loss?

Researchers developed AOD-9604 to investigate whether a growth-hormone-related fragment could affect fat metabolism without reproducing all of growth hormone's effects. Laboratory and animal findings helped motivate human development. They do not establish meaningful weight loss in people, selective loss of “belly fat,” preserved muscle or a safe wellness treatment. The FDA review distinguishes AOD-9604 from native growth-hormone fragments and examines both free-base and acetate forms; a similar name is not enough to establish that products are interchangeable. FDA briefing, identity and clinical-effectiveness sections.

One development program, several kinds of documents

The following records answer different questions. The main clinical record available here includes original registry information, a published safety report, a developer's announcement and FDA's later appraisal. It is not a complete set of published trial reports with participant-level data.

Early human studies: biological activity was not proof of weight loss

Evidence kind: short development summaries. FDA's 2024 briefing describes small early comparisons, including intravenous and oral studies. Some measured increases in circulating non-esterified fatty acids—a marker related to fat metabolism. The reviewer found no statistically significant weight-loss advantage over placebo in the early studies it summarized and noted small samples, unclear study parameters and limited numerical detail. FDA briefing, page 20.

A change in a blood marker is a reason to investigate a mechanism. It is not the same outcome as sustained weight loss, reduced waist size or better health. These brief summaries cannot establish that a person using a different preparation will lose fat.

A 300-person report: a favorable signal with limited reporting

Evidence kind: a conference abstract appraised by FDA. A 2005 abstract described a randomized, double-blind, placebo-controlled oral study in 300 adults with obesity over 12 weeks. It reported greater weight loss with active treatment and a complex response across groups, including a favorable finding among women in one group. FDA noted that the differences were small, their therapeutic importance was unclear, and the abstract lacked enough methods and results for confident interpretation. The agency did not locate a full publication of that study's methods and results. FDA briefing, pages 20–21.

The developer's later announcement also describes the earlier trial: its best study group fell short on the primary analysis (P=0.10 against a required 0.05), despite a significant female subgroup finding. That distinction is easy to lose in a favorable headline. Company announcement, February 21, 2007, PDF page 8.

Retain the favorable report without making it stronger than its documentation. An abstract, a subgroup finding and a complete confirmatory trial are different levels of evidence. Calling the entire record positive because of this abstract would omit the larger study that followed.

OPTIONS: the larger oral trial did not establish its main weight-loss benefit

Evidence kind: a registered randomized trial, with results described in the developer's announcement and FDA review. OPTIONS, also called METAOD006, studied oral AOD-9604 versus placebo in adults with obesity, alongside a diet-and-exercise program. It was double-blind. The FDA briefing and the 2013 publication agree that 502 people were randomized. FDA briefing, pages 21–22; published safety report.

Primary weight endpoint: Weight change after 12 weeks, compared with placebo.
Full treatment period: 24 weeks; the registry lists 24-week weight change as a secondary outcome and safety/tolerability over 24 weeks as another primary outcome.
Reported result: No significant difference in weight loss at the primary endpoint; the company also reported insufficient separation from placebo at 24 weeks.

“A 24-week study” and “a 12-week primary weight endpoint” can both be correct. They describe different parts of the same trial. The Australian New Zealand Clinical Trials Registry identifies it as ACTRN12605000067673, registered August 2, 2005 and last updated September 14, 2007. The entry documents the study plan, not a complete results paper. Its old target of 360 participants is not the final randomized count; the final-count field is blank. Original trial registration.

Enrollment counts need another qualification. FDA's briefing reports 536 enrolled, while the 2013 paper says 534 enrolled. Both identify 502 randomized. We cannot reconcile the two enrollment totals from the inspected documents, so neither is substituted for the randomized population. These are not two separate large trials. The company filing lists 502 people at randomization, 408 attending at week 12 and 357 at week 24. Attendance counts are not a complete account of the analysis population or missing-data methods; those details cannot be reconstructed from the summary. Original company filing, PDF pages 8–9.

The developer announced on February 21, 2007 that it was ending development for obesity after these results. FDA later stated that it had not found a detailed publication of the trial's methods and effectiveness results in the medical literature. This limits independent assessment of the full analysis; it does not turn the negative primary comparison into a positive result or prove that no human trial existed. A registry outside ClinicalTrials.gov is still a trial record. FDA clinical-effectiveness appraisal; December 4, 2024 meeting transcript, Topic 2, pages 22–23.

The 2013 paper: safety reporting from the same six studies

Evidence kind: a published summary of existing trials. Stier, Vos and Kenley summarized six studies conducted during the development program, including METAOD005 and METAOD006. The paper's purpose was safety and tolerability. Its publication date does not mean a new set of six weight-loss trials happened in 2013, and it does not independently confirm weight-loss benefit. The developer funded all six trials; the authors disclosed company employment, consulting or financial relationships. Original safety report, methods and declarations.

The authors reported similar tolerability across groups and no detected antibodies in the selected participants tested. Those observations address particular monitored outcomes in oral and intravenous studies. They do not establish the effectiveness of AOD-9604, exclude uncommon or long-term harms, or validate an injected product sold today. FDA's later review found important limits in the adverse-event detail, study durations and case information. FDA safety appraisal, pages 33–36.

What side effects and formulation gaps matter?

The historical studies reported headaches and gastrointestinal symptoms such as diarrhea or flatulence. Some serious events were also described. Investigators considered several reported cancers unrelated to treatment, while FDA found the information insufficient to settle that question; it also could not identify a safety signal from the limited, heterogeneous case data. This is neither proof that AOD-9604 causes cancer nor a basis for dismissing the uncertainty. Small, short studies and sparse case descriptions cannot reliably resolve uncommon harms. FDA briefing, pages 34–36 and footnote 68.

Oral and intravenous studies do not establish the safety or effectiveness of subcutaneous products. FDA's 2024 review found no human exposure information for the proposed subcutaneous or transdermal uses in its search. That is a dated finding about the reviewed record, not a claim that no such research could ever exist. Route, formulation, impurities and product quality can change the relevant evidence.

FDA's compounded-substance safety page, marked current April 22, 2026 and checked November 9, warns about potential immunogenicity, peptide-related impurities and active-ingredient characterization for AOD-9604. It says safety information is absent or limited and notes serious events with unclear causality. The agency's concern is not a measured harm rate for every preparation. FDA safety entry.

Three checks for an AOD-9604 “results” claim

“It was studied for 24 weeks, so it worked.” Duration is not an outcome. In OPTIONS, check the 12-week primary weight comparison and the separately reported 24-week result; neither established the claimed weight-loss advantage.
“A paper reports six successful studies.” Check what the paper actually evaluated. A safety summary reusing six earlier trials does not create six new effectiveness confirmations. More citations can refer to the same participants.
“The trials prove this injection is safe.” Match the preparation, route, people and monitored outcomes. The inspected oral/intravenous development record does not establish that claim for a subcutaneous product.

If a headline supplies no original source, comparison, route or endpoint, leave the claim unverified. A testimonial or before-and-after photograph cannot supply the missing control group. The sources below let you inspect the record without treating uncertainty as either a benefit promise or proof of universal harm.

This guide gives no dosing, administration, purchase or weight-loss treatment plan. For questions about weight management, discuss the actual goal, established options and risks with a qualified clinician. Return to the AOD-9604 profile and retained additional documents or explore other peptide topics. Different compounds and approved products need their own evidence; a growth-hormone-related name does not transfer another medicine's results.

Scope of the historical FDA review

The briefing memorandum is dated November 5, 2024 and supported the December 4, 2024 Pharmacy Compounding Advisory Committee discussion. Its cover says it was background for an advisory process, not a final determination. The briefing and transcript are separate documents about the same evaluation, not independent clinical trials. This guide does not determine current compounding permission, approval or legal status in every jurisdiction.

Sources6 linked sources

Selected-source and editorial check: November 9, 2026. Original agency documents, the historical registry and published safety report were read. Underlying unpublished full efficacy reports and participant-level data were not available for independent review. This is not a complete literature review, clinician approval or assessment of every current formulation or jurisdiction.

AOD-9604: follow the human weight-loss evidence.